SEC authorities said they filed the complaint in a Boston court against two former Ariad executives, Maureen Curran and Susan Dubuc, who served as Ariad’s senior and associate director of pharmacovigilance and risk management, respectively. Officials also charged Harold Altvater, the husband of another former Ariad employee.
The complaint alleges Ms. Curran, Ms. Dubuc and Mr. Altvater used private information to illegally trade Ariad shares prior to the public announcement of a regulatory decision that would influence sales of one of the company’s cancer drugs, according to the report.
Ms. Curran agreed to pay $20,000 in fines through a settlement and Ms. Dubuc agreed to pay more than $6,000. Mr. Altvater did not respond to The Boston Globe’s request for comment.
More articles on supply chain:
Viewpoint: 4 insights into postapproval monitoring of medical devices
Interchangeable biosimilars will hit market within 2 years, says FDA leader
Hospira recall drives 2 other drug companies to pull injectables from market
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
